Base de dados : MEDLINE
Pesquisa : D08.811.277.656.262.500.096 [Categoria DeCS]
Referências encontradas : 1174 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 118 ir para página                         

  1 / 1174 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28650791
[Au] Autor:Hasija P; Sachdev V; Mathur S; Rath R
[Ti] Título:Deproteinizing Agents as an Effective Enamel Bond Enhancer-An in Vitro Study.
[So] Source:J Clin Pediatr Dent;41(4):280-283, 2017.
[Is] ISSN:1053-4628
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The aim of this study was to compare the effect of different deproteinizing agents on shear bond strength of composite to primary teeth enamel. STUDY DESIGN: Forty sound primary molars divided in 4 groups of 10 teeth each. In control group 1, enamel was etched for 60 seconds with 37% phosphoric acid and rinsed with water. Group 2: after acid etching deproteinizing agent 5 % sodium hypochlorite was applied for 60 seconds and rinsed. Group 3: after acid etching deproteinizing agent papain gel was applied for 60 seconds and rinsed. Group 4: after acid etching deproteinizing agent bromelain gel applied for 60 seconds and rinsed. Following this, bonding agent was applied to treated enamel surface and composite resin disc were build. Samples were then tested for shear bond strength using Universal Testing Machine. RESULTS: Mean SBS was highest for group 4 and lowest for group 1. No statistically significant difference (p value >0.05) was found between all the four groups. CONCLUSION: Among deproteinizing agents, deproteinization when carried out with bromelain gel and sodium hypochlorite showed effective bond strength as compared to papain.
[Mh] Termos MeSH primário: Ataque Ácido Dentário/métodos
Bromelaínas/farmacologia
Colagem Dentária/métodos
Papaína/farmacologia
Ácidos Fosfóricos/farmacologia
Hipoclorito de Sódio/farmacologia
[Mh] Termos MeSH secundário: Seres Humanos
Resistência ao Cisalhamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Phosphoric Acids); 9001-00-7 (Bromelains); DY38VHM5OD (Sodium Hypochlorite); EC 3.4.22.2 (Papain)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:D
[Da] Data de entrada para processamento:170627
[St] Status:MEDLINE
[do] DOI:10.17796/1053-4628-41.4.280


  2 / 1174 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28362352
[Au] Autor:Muhammad Auwal S; Zarei M; Abdul-Hamid A; Saari N
[Ad] Endereço:Department of Food Science, Faculty of Food Science and Technology, University Putra Malaysia, Serdang, Selangor 43400, Malaysia. samuhammad.bch@buk.edu.ng.
[Ti] Título:Optimization of Bromelain-Aided Production of Angiotensin I-Converting Enzyme Inhibitory Hydrolysates from Stone Fish Using Response Surface Methodology.
[So] Source:Mar Drugs;15(4), 2017 Mar 31.
[Is] ISSN:1660-3397
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:The stone fish is an under-utilized sea cucumber with many nutritional and ethno-medicinal values. This study aimed to establish the conditions for its optimum hydrolysis with bromelain to generate angiotensin I-converting enzyme (ACE)-inhibitory hydrolysates. Response surface methodology (RSM) based on a central composite design was used to model and optimize the degree of hydrolysis (DH) and ACE-inhibitory activity. Process conditions including pH (4-7), temperature (40-70 °C), enzyme/substrate (E/S) ratio (0.5%-2%) and time (30-360 min) were used. A pH of 7.0, temperature of 40 °C, E/S ratio of 2% and time of 240 min were determined using a response surface model as the optimum levels to obtain the maximum ACE-inhibitory activity of 84.26% at 44.59% degree of hydrolysis. Hence, RSM can serve as an effective approach in the design of experiments to improve the antihypertensive effect of stone fish hydrolysates, which can thus be used as a value-added ingredient for various applications in the functional foods industries.
[Mh] Termos MeSH primário: Inibidores da Enzima Conversora de Angiotensina/química
Inibidores da Enzima Conversora de Angiotensina/farmacologia
Bromelaínas/química
Peixes/metabolismo
Hidrolisados de Proteína/química
[Mh] Termos MeSH secundário: Animais
Anti-Hipertensivos/química
Anti-Hipertensivos/farmacologia
Concentração de Íons de Hidrogênio
Hidrólise/efeitos dos fármacos
Temperatura Ambiente
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Antihypertensive Agents); 0 (Protein Hydrolysates); 9001-00-7 (Bromelains)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170401
[St] Status:MEDLINE


  3 / 1174 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28341257
[Au] Autor:Schulz A; Perbix W; Shoham Y; Daali S; Charalampaki C; Fuchs PC; Schiefer J
[Ad] Endereço:Department of Plastic Surgery, Hand Surgery, Burn Center, University of Witten/Herdecke, Cologne-Merheim Medical Center (CMMC), Cologne, Germany. Electronic address: schulza@kliniken-koeln.de.
[Ti] Título:Our initial learning curve in the enzymatic debridement of severely burned hands-Management and pit falls of initial treatments and our development of a post debridement wound treatment algorithm.
[So] Source:Burns;43(2):326-336, 2017 Mar.
[Is] ISSN:1879-1409
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Excisional surgical debridement (SD) is still the gold standard in the treatment of deeply burned hands, though the intricate anatomy is easily damaged. Previous studies demonstrated that enzymatic debridement with the bromelain debriding agent NexoBrid (EDNX) is more selective and thus can preserve viable tissue with excellent outcome results. So far no method paper has been published presenting different treatment algorithms in this new field. Therefore our aim was to close this gap by presenting our detailed learning curve in EDNX of deeply burned hands. METHODS: We conducted a single-center prospective observational clinical trial treating 20 patients with deeply burned hands with EDNX. Different anaesthetic procedures, debridement and wound treatment algorithms were compared and main pitfalls described. RESULTS: EDNX was efficient in 90% of the treatments though correct wound bed evaluation was challenging and found unusual compared to SD. Post EDNX surprisingly the majority of the burn surface area was found overestimated (18 wounds). Finally we simplified our process and reduced treatment costs by following a modified treatment algorithm and treating under plexus anaesthesia bedside through a single nurse and one burn surgeon solely. Suprathel could be shown to be an appropriate dressing for wound treatment after EDNX. Complete healing (less 5% rest defect) was achieved at an average of day 28. CONCLUSION: EDNX in deep burned hands is promising regarding handling and duration of the treatment, efficiency and selectivity of debridement, healing potential and early rehabilitation. Following our treatment algorithm EDNX can be performed easily and even without special knowledge in burn wound depth evaluation.
[Mh] Termos MeSH primário: Bromelaínas/uso terapêutico
Queimaduras/terapia
Desbridamento/métodos
Traumatismos da Mão/terapia
Curva de Aprendizado
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Algoritmos
Anestesia/métodos
Bandagens
Queimaduras/reabilitação
Feminino
Traumatismos da Mão/reabilitação
Seres Humanos
Masculino
Meia-Idade
Manejo da Dor/métodos
Estudos Prospectivos
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
9001-00-7 (Bromelains)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170326
[St] Status:MEDLINE


  4 / 1174 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28238440
[Au] Autor:Matagne A; Bolle L; El Mahyaoui R; Baeyens-Volant D; Azarkan M
[Ad] Endereço:Université de Liège, Laboratoire d'Enzymologie et Repliement des Protéines, Centre d'Ingénierie des Protéines, Liège, Belgium.
[Ti] Título:The proteolytic system of pineapple stems revisited: Purification and characterization of multiple catalytically active forms.
[So] Source:Phytochemistry;138:29-51, 2017 Jun.
[Is] ISSN:1873-3700
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Crude pineapple proteases extract (aka stem bromelain; EC 3.4.22.4) is an important proteolytic mixture that contains enzymes belonging to the cysteine proteases of the papain family. Numerous studies have been reported aiming at the fractionation and characterization of the many molecular species present in the extract, but more efforts are still required to obtain sufficient quantities of the various purified protease forms for detailed physicochemical, enzymatic and structural characterization. In this work, we describe an efficient strategy towards the purification of at least eight enzymatic forms. Thus, following rapid fractionation on a SP-Sepharose FF column, two sub-populations with proteolytic activity were obtained: the unbound (termed acidic) and bound (termed basic) bromelain fractions. Following reversible modification with monomethoxypolyethylene glycol (mPEG), both fractions were further separated on Q-Sepharose FF and SP-Sepharose FF, respectively. This procedure yielded highly purified molecular species, all titrating ca. 1 mol of thiol group per mole of enzyme, with distinct biochemical properties. N-terminal sequencing allowed identifying at least eight forms with proteolytic activity. The basic fraction contained previously identified species, i.e. basic bromelain forms 1 and 2, ananain forms 1 and 2, and comosain (MEROPS identifier: C01.027). Furthermore, a new proteolytic species, showing similarities with basic bomelain forms 1 and 2, was discovered and termed bromelain form 3. The two remaining species were found in the acidic bromelain fraction and were arbitrarily named acidic bromelain forms 1 and 2. Both, acidic bromelain forms 1, 2 and basic bromelain forms 1, 2 and 3 are glycosylated, while ananain forms 1 and 2, and comosain are not. The eight protease forms display different amidase activities against the various substrates tested, namely small synthetic chromogenic compounds (DL-BAPNA and Boc-Ala-Ala-Gly-pNA), fluorogenic compounds (like Boc-Gln-Ala-Arg-AMC, Z-Arg-Arg-AMC and Z-Phe-Arg-AMC), and proteins (azocasein and azoalbumin), suggesting a specific organization of their catalytic residues. All forms are completely inhibited by specific cysteine and cysteine/serine protease inhibitors, but not by specific serine and aspartic protease inhibitors, with the sole exception of pepstatin A that significantly affects acidic bromelain forms 1 and 2. For all eight protease forms, inhibition is also observed with 1,10-phenanthrolin, a metalloprotease inhibitor. Metal ions (i.e. Mn , Mg and Ca ) showed various effects depending on the protease under consideration, but all of them are totally inhibited in the presence of Zn . Mass spectrometry analyses revealed that all forms have a molecular mass of ca. 24 kDa, which is characteristic of enzymes belonging to the papain-like proteases family. Far-UV CD spectra analysis further supported this analysis. Interestingly, secondary structure calculation proves to be highly reproducible for all cysteine proteases of the papain family tested so far (this work; see also Azarkan et al., 2011; Baeyens-Volant et al., 2015) and thus can be used as a test for rapid identification of the classical papain fold.
[Mh] Termos MeSH primário: Ananas/química
Cisteína Proteases/isolamento & purificação
Extratos Vegetais/análise
Proteínas de Plantas/isolamento & purificação
Proteólise
[Mh] Termos MeSH secundário: Bromelaínas/análise
Fracionamento Químico/métodos
Cisteína Endopeptidases/análise
Cisteína Proteases/análise
Proteínas de Plantas/análise
Caules de Planta/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Plant Extracts); 0 (Plant Proteins); 9001-00-7 (Bromelains); EC 3.4.- (Cysteine Proteases); EC 3.4.22.- (Cysteine Endopeptidases); EC 3.4.22.- (comosain); EC 3.4.22.31 (ananain); EC 3.4.22.32 (stem bromelain)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170501
[Lr] Data última revisão:
170501
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170228
[St] Status:MEDLINE


  5 / 1174 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28205185
[Au] Autor:Desideri I; Francolini G; Becherini C; Terziani F; Delli Paoli C; Olmetto E; Loi M; Perna M; Meattini I; Scotti V; Greto D; Bonomo P; Sulprizio S; Livi L
[Ad] Endereço:Department of Clinical and Experimental Biomedical Sciences, University of Florence, Viale Morgagni 85, 50134, Florence, Italy. isacco.desideri@unifi.it.
[Ti] Título:Use of an alpha lipoic, methylsulfonylmethane and bromelain dietary supplement (Opera ) for chemotherapy-induced peripheral neuropathy management, a prospective study.
[So] Source:Med Oncol;34(3):46, 2017 Mar.
[Is] ISSN:1559-131X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Chemotherapy-induced peripheral neuropathy (CIPN) is a major clinical problem associated with a number of cytotoxic agents. OPERA (GAMFARMA srl, Milan, Italy) is a new dietary supplement where α-lipoic acid, Boswellia Serrata, methylsulfonylmethane and bromelain are combined in a single capsule. The aim of this prospective study was to determine the efficacy and safety of OPERA supplementation in a series of patients affected by CIPN. We selected 25 subjects with CIPN evolving during or after chemotherapy with potentially neurotoxic agents. Patients were enrolled at the first clinical manifestation of neuropathy. CIPN was assessed at the enrollment visit and subsequently repeated every 3 weeks until 12 weeks. Primary endpoint was the evaluation of changes of measured scores after 12 weeks of therapy compared to baseline evaluation. Secondary endpoints were the evaluation of neuropathy reduction at 12 weeks after beginning of therapy with OPERA . Analysis of VAS data showed reduction in pain perceived by patients. According to NCI-CTC sensor and motor score, mISS scale and TNSc scale, both pain and both sensor and motor neuropathic impairment decreased after 12 weeks of treatments. Treatment with OPERA supplement was well tolerated; no increase in the toxicity profile of any of the therapeutic regimen that the patients were undergoing was reported. OPERA was able to improve CIPN symptoms in a prospective series of patients treated with neurotoxic chemotherapy, with no significant toxicity or interaction. Prospective RCT in a selected patients' population is warranted to confirm its promising activity.
[Mh] Termos MeSH primário: Bromelaínas/administração & dosagem
Dimetil Sulfóxido/administração & dosagem
Doenças do Sistema Nervoso Periférico/induzido quimicamente
Doenças do Sistema Nervoso Periférico/tratamento farmacológico
Sulfonas/administração & dosagem
Ácido Tióctico/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Idoso
Antineoplásicos/efeitos adversos
Antineoplásicos/uso terapêutico
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Suplementos Nutricionais
Feminino
Seres Humanos
Masculino
Meia-Idade
Neoplasias/tratamento farmacológico
Neurotoxinas/efeitos adversos
Neurotoxinas/uso terapêutico
Estudos Prospectivos
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Neurotoxins); 0 (Sulfones); 73Y7P0K73Y (Thioctic Acid); 9001-00-7 (Bromelains); 9H4PO4Z4FT (dimethyl sulfone); YOW8V9698H (Dimethyl Sulfoxide)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170217
[St] Status:MEDLINE
[do] DOI:10.1007/s12032-017-0907-4


  6 / 1174 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28069129
[Au] Autor:Huang Y; Ruan G; Qin Z; Li H; Zheng Y
[Ad] Endereço:Guangxi Key Laboratory of Electrochemical and Magnetochemical Function Materials, College of Chemistry and Bioengineering, Guilin University of Technology, Guangxi 541004, China.
[Ti] Título:Antioxidant activity measurement and potential antioxidant peptides exploration from hydrolysates of novel continuous microwave-assisted enzymolysis of the Scomberomorus niphonius protein.
[So] Source:Food Chem;223:89-95, 2017 May 15.
[Is] ISSN:0308-8146
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A novel continuous microwave-assisted enzymatic digestion (cMAED) method is proposed for the digestion of protein from Scomberomorus niphonius to obtain potential antioxidant peptides. In this study, bromelain was found to have a high capacity for the digestion of the Scomberomorus niphonius protein. The following cMAED conditions were investigated: protease species, microwave power, temperature, bromelain content, acidity of the substrate solution, and incubation time. At 400W, 40°C, 1500U·g bromelain, 20% substrate concentration, pH 6.0 and 5min incubation, the degree of hydrolysis and total antioxidant activity of the hydrolysates were 15.86% and 131.49µg·mL , respectively. The peptide analyses showed that eight of the potential antioxidant peptide sequences, which ranged from 502.32 to 1080.55Da with 4-10 amino acid residues, had features typical of well-known antioxidant proteins. Thus, the new cMAED method can be useful to obtain potential antioxidant peptides from protein sources, such as Scomberomorus niphonius.
[Mh] Termos MeSH primário: Antioxidantes/análise
Bromelaínas/análise
Proteínas de Peixes/análise
Micro-Ondas
Fragmentos de Peptídeos/análise
[Mh] Termos MeSH secundário: Animais
Antioxidantes/metabolismo
Antioxidantes/efeitos da radiação
Bromelaínas/metabolismo
Bromelaínas/efeitos da radiação
Proteínas de Peixes/metabolismo
Peixes
Hidrólise/efeitos da radiação
Oxirredução/efeitos da radiação
Fragmentos de Peptídeos/metabolismo
Fragmentos de Peptídeos/efeitos da radiação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Fish Proteins); 0 (Peptide Fragments); 9001-00-7 (Bromelains); EC 3.4.22.32 (stem bromelain)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170111
[St] Status:MEDLINE


  7 / 1174 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27899289
[Au] Autor:Agarwal S; Chaudhary B; Bist R
[Ad] Endereço:Department of Bioscience and Biotechnology, Banasthali University, Rajasthan 304022, India. Electronic address: sonam.2mits@gmail.com.
[Ti] Título:Protective propensity of bacoside A and bromelain on renal cholinesterases, γ-Aminobutyric acid and serotonin level of Mus musculus intoxicated with dichlorvos.
[So] Source:Chem Biol Interact;261:139-144, 2017 Jan 05.
[Is] ISSN:1872-7786
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Current study established a protective action of bacoside A and bromelain against the toxic effects of dichlorvos in kidneys of mice. Experimental design included five groups. The first group was control. Mice of groups II, III and IV were administered doses of dichlorvos, bromelain and bacoside A respectively. In group V, mice were treated with both the antioxidants (bacoside A and bromelain) and dichlorvos. After 21 days of exposure of different doses, levels of acetylcholinesterase (AChE), butyrylcholinesterase (BChE), γ-aminobutyric acid (GABA) and serotonin were measured in renal tissues. Dichlorvos significantly reduced the kidney AChE (p < 0.001), BChE (p < 0.01) and GABA level (p < 0.01) compared to control. A simultaneous significant elevation in the serotonin level (p < 0.01) was recorded after dichlorvos exposure. Concomitant exposure of bacoside A and bromelain followed by dichlorvos treatment in group V not only restored, but increased the renal cholinesterases and GABA level. Meanwhile, a significant decline in serotonin level (p < 0.001) was revealed, compared to dichlorvos exposed mice. Bacoside A and bromelain occupy a tremendous antioxidant action in the mice kidneys and a combination of the same ameliorates the renal toxicity induced by dichlorvos.
[Mh] Termos MeSH primário: Acetilcolinesterase/metabolismo
Bromelaínas/farmacologia
Butirilcolinesterase/metabolismo
Diclorvós/toxicidade
Rim/enzimologia
Saponinas/farmacologia
Serotonina/metabolismo
Triterpenos/farmacologia
Ácido gama-Aminobutírico/metabolismo
[Mh] Termos MeSH secundário: Animais
Rim/efeitos dos fármacos
Rim/patologia
Masculino
Camundongos
Substâncias Protetoras/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Protective Agents); 0 (Saponins); 0 (Triterpenes); 0 (bacoside A); 333DO1RDJY (Serotonin); 56-12-2 (gamma-Aminobutyric Acid); 7U370BPS14 (Dichlorvos); 9001-00-7 (Bromelains); EC 3.1.1.7 (Acetylcholinesterase); EC 3.1.1.8 (Butyrylcholinesterase); EC 3.4.22.32 (stem bromelain)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161201
[St] Status:MEDLINE


  8 / 1174 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27889883
[Au] Autor:Chandanwale A; Langade D; Sonawane D; Gavai P
[Ad] Endereço:Department of Orthopaedics, Grant Medical College and Sir J.J. Group of Hospitals, Byculla, Mumbai, 400 007, India.
[Ti] Título:A Randomized, Clinical Trial to Evaluate Efficacy and Tolerability of Trypsin:Chymotrypsin as Compared to Serratiopeptidase and Trypsin:Bromelain:Rutoside in Wound Management.
[So] Source:Adv Ther;34(1):180-198, 2017 Jan.
[Is] ISSN:1865-8652
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Systemic enzyme therapy can play an important role in maintaining normal inflammatory processes within the body and thereby helps support and speed up healing. In the course of the anti-inflammatory action, enzymes degrade damaged cells and necrotic material and, through the inactivation of mediators and toxic products, they restrict the edema and pain. METHOD: The study conducted at Grant Medical College, Mumbai, India was a clinical trial comparing the efficacy and tolerability of three oral enzyme treatment groups-oral tablets containing trypsin:chymotrypsin (TC) (Chymoral Forte ), serratiopeptidase (S) 5 mg oral tablets, and oral enzyme tablets containing trypsin 48 mg, bromelain 90 mg, and rutoside 100 mg (TBR)-to evaluate their healing potential in surgical wounds after orthopedic surgery. RESULTS: A total of 75 patients were screened, randomized, and divided into three groups in 1:1:1 ratio receiving either of the three treatments. In the TC group, erythema was significantly reduced from 3.44 on day 3 to 1.16 on day 10 (p < 0.01). There was significantly better reduction in erythema scores in the TC group as compared to S and TBR groups (p < 0.05) at each follow-up visit. Similarly reduction in the local irritation, wound discharge, edema, induration, and tenderness score with TC treatment at the end of the study was significantly higher than that observed in the other two groups. In addition TC showed significant reduction in pain on the VAS scale (p < 0.01). Global assessment of response to therapy for efficacy and tolerability was reported to be good to excellent in 88% and 92% of the patients on TC as compared to 12% and 8% with S and 12% and 8% with TBR. CONCLUSION: TC provides a better resolution of symptoms of inflammation after orthopedic surgery as compared to S and TBR, thus facilitating better wound healing. Further studies are warranted to confirm the findings. TRIAL REGISTRATION: Clinical Trial Registry of India (Reg. No. CTRI/2011/07/001920).
[Mh] Termos MeSH primário: Anti-Inflamatórios/uso terapêutico
Bromelaínas/uso terapêutico
Quimotripsina/uso terapêutico
Peptídeo Hidrolases/uso terapêutico
Rutina/uso terapêutico
Tripsina/uso terapêutico
Ferimentos e Lesões/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Bromelaínas/administração & dosagem
Bromelaínas/efeitos adversos
Quimotripsina/administração & dosagem
Quimotripsina/efeitos adversos
Combinação de Medicamentos
Quimioterapia Combinada
Eritema/tratamento farmacológico
Feminino
Seres Humanos
Masculino
Meia-Idade
Peptídeo Hidrolases/administração & dosagem
Peptídeo Hidrolases/efeitos adversos
Estudos Prospectivos
Rutina/administração & dosagem
Rutina/efeitos adversos
Tripsina/administração & dosagem
Tripsina/efeitos adversos
Cicatrização/efeitos dos fármacos
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE IV; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Drug Combinations); 5G06TVY3R7 (Rutin); 8076-22-0 (chymotrypsin, trypsin drug combination); 9001-00-7 (Bromelains); EC 3.4.- (Peptide Hydrolases); EC 3.4.21.1 (Chymotrypsin); EC 3.4.21.4 (Trypsin); NL053ABE4J (serratiopeptidase)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:161128
[St] Status:MEDLINE
[do] DOI:10.1007/s12325-016-0444-0


  9 / 1174 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27855525
[Au] Autor:São Paulo Barretto Miranda ÍK; Fontes Suzart Miranda A; Souza FV; Vannier-Santos MA; Pirovani CP; Pepe IM; Rodowanski IJ; Ferreira KT; Mendes Souza Vaz L; de Assis SA
[Ad] Endereço:a Health Department , State University of Feira de Santana (UEFS) , Feira de Santana , Brazil.
[Ti] Título:The biochemical characterization, stabilization studies and the antiproliferative effect of bromelain against B16F10 murine melanoma cells.
[So] Source:Int J Food Sci Nutr;68(4):442-454, 2017 Jun.
[Is] ISSN:1465-3478
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The current study aims to extract bromelain from different parts (stem, crown, peels, pulp and leaves) of Ananas comosus var. comosus AGB 772; to determine of optimum pH and temperature; to test bromelain stability in disodium EDTA and sodium benzoate, and to investigate its pharmacological activity on B16F10 murine melanoma cells in vitro. The highest enzymatic activity was found in bromelain extracted from the pulp and peel. The optimum bromelain pH among all studied pineapple parts was 6.0. The optimum temperature was above 50 °C in all bromelain extracts. The fluorescence analysis confirmed the stability of bromelain in the presence of EDTA and sodium benzoate. Bromelain was pharmacologically active against B16F10 melanoma cells and it was possible verifying approximately 100% inhibition of tumor cell proliferation in vitro. Since bromelain activity was found in different parts of pineapple plants, pineapple residues from the food industry may be used for bromelain extraction.
[Mh] Termos MeSH primário: Ananas/química
Antineoplásicos Fitogênicos/farmacologia
Bromelaínas/farmacologia
[Mh] Termos MeSH secundário: Animais
Antineoplásicos Fitogênicos/química
Bromelaínas/química
Linhagem Celular Tumoral
Proliferação Celular/efeitos dos fármacos
Camundongos
Componentes Aéreos da Planta/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents, Phytogenic); 9001-00-7 (Bromelains)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161119
[St] Status:MEDLINE
[do] DOI:10.1080/09637486.2016.1254599


  10 / 1174 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27790704
[Au] Autor:Ramli AN; Aznan TN; Illias RM
[Ad] Endereço:Faculty of Industrial Science and Technology, Universiti Malaysia Pahang, Lebuhraya Tun Razak, 26300, Gambang, Kuantan, Pahang Darul Makmur, Malaysia.
[Ti] Título:Bromelain: from production to commercialisation.
[So] Source:J Sci Food Agric;97(5):1386-1395, 2017 Mar.
[Is] ISSN:1097-0010
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Bromelain is a mixture of proteolytic enzymes found in pineapple (Ananas comosus) plants. It can be found in several parts of the pineapple plant, including the stem, fruit, leaves and peel. High demand for bromelain has resulted in gradual increases in bromelain production. These increases have led to the need for a bromelain production strategy that yields more purified bromelain at a lower cost and with fewer production steps. Previously, bromelain was purified by conventional centrifugation, ultrafiltration and lyophilisation. Recently, the development of more modern purification techniques such as gel filtration, ion exchange chromatography, affinity chromatography, aqueous two-phase extraction and reverse micelle chromatography has resulted in increased industrial bromelain production worldwide. In addition, recombinant DNA technology has emerged as an alternative strategy for producing large amounts of ultrapure bromelain. An up-to-date compilation of data regarding the commercialisation of bromelain in the clinical, pharmaceutical and industrial fields is provided in this review. © 2016 Society of Chemical Industry.
[Mh] Termos MeSH primário: Bromelaínas/isolamento & purificação
Tecnologia de Alimentos/métodos
[Mh] Termos MeSH secundário: Ananas/química
Ananas/enzimologia
Biotecnologia/métodos
Bromelaínas/química
DNA Recombinante
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (DNA, Recombinant); 9001-00-7 (Bromelains)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161030
[St] Status:MEDLINE
[do] DOI:10.1002/jsfa.8122



página 1 de 118 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde